AbbVie posts higher revenue in 2025, led by immunology & neuroscience growth

Immunology remained AbbVie’s largest and fastest-growing segment, delivering $30.41 billion in global net revenues,

FDA launches PreCheck program to bring drug manufacturing back to US

The program seeks to boost regulatory predictability, support construction of US-based manufacturing sites

Siemens Healthineers launches €10 million R&D hub in Swords, Ireland

The facility is dedicated to breakthrough innovations in laboratory instruments that detect infectious diseases, cancer, and blood disorders

Arctic Vision expands global reach with acquisition of MDCO Technology’s ophthalmic device business

Onchilles Pharma gets FDA green light for first-in-human trials of breakthrough cancer therapy

N17350 is the company’s first-in-class tumor-directed therapeutic, designed to harness the ELANE pathway

Pfizer’s monthly obesity drug shows breakthrough weight loss in Phase 2b trial

The study tested whether PF’3944 could maintain efficacy when switching from weekly to monthly injections and remain safe and well-tolerated

Epigenica launches EpiFinder Analysis Service to accelerate Epigenomic research

The new service delivers end-to-end support, managing every stage of an epigenomics project

Wanbury achieves first sales invoicing and commercial shipment milestone

This achievement validates global demand and catapults Wanbury into high-growth acceleration

Zydus Wellness net sales up by 113.7% in Q3 FY26

Glucon-D maintained its leadership position with a 59% MAT market share

NATCO receives FDA's tentative approval for Erdafitinib tablets

NATCO’s Erdafitinib is indicated for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma harbouring susceptible FGFR3 genetic alteration